Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients

Title
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients
Authors
김철수
Issue Date
2013
Publisher
AMERICAN JOURNAL OF HEMATOLOGY
Series/Report no.
AMERICAN JOURNAL OF HEMATOLOGY ; Vol.88 no.1 Startpage 10 Endpage 15
Abstract
We performed a phase II trial to evaluate the efficacy and safety of the modified fludarabine, cytarabine, andattenuated-dose idarubicin (m-FLAI) regimen in elderly acute myeloid leukemia (AML) patients. Elderly (60years) AML patients who had not previously received chemotherapy were enrolled in the study. Patientsreceived two consecutive cycles of m-FLAI chemotherapy as an induction. The m-FLAI regimen comprisedfludarabine (25 mg/m2, days 1?4), cytarabine (1,000 mg/m2, days 1?4), and attenuated-dose idarubicin (5 mg/m2, days 1?3). The primary end point was complete remission (CR) rate. Secondary end points were overallsurvival (OS), event-free survival (EFS), and treatment-related mortality (TRM). There were 108 patients (me-dian age 68.4 years, M:F 5 64:44) enrolled in the study. CR was achieved in 56.5% of patients, and the TRMrate was 21.3%. Median OS and median EFS were 10.2 and 6.6 months, respectively. The mortality at 30 and60 days was 15 and 21%, respectively. Performance status and comorbidity did not have prognostic value inthis patient cohort. Bone marrow expression of CD117 was associated with increased EFS and OS. m-FLAI isan effective induction regimen for previously untreated AML in elderly patients. In addition, bone-marrowCD117 expression is an independent favorable prognostic factor in elderly AML patients.
URI
http://dspace.inha.ac.kr/handle/10505/31283
ISSN
0361-8609
Appears in Collections:
Medical School/College of Medicine (의학전문대학원/의과대학) > Medical Science (의학) > Journal Papers, Reports(의학 논문, 보고서)

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse